Angiotensin Converting Enzyme (ACE2), Brain, Gut Dysbiosis in Pulmonary Hypertension

Completed

Conditions studied: Pulmonary Arterial Hypertension

In brief

Pulmonary arterial hypertension (PAH) is fatal with right heart failure due to raised pulmonary vascular pressure. Gut dysbiosis was identified in animals with pulmonary hypertension. Deidentified human samples will be tested for gut dysbiosis in PAH, circulating bacterial metabolites and markers of inflammation and gut leakiness. The gut microbiome and circulating metabolites, markers of inflammation and gut leakiness of PAH patients and healthy subjects will be compared in deidentified fecal samples and blood.

Key facts

Study ID

NCT04104490

Run by

University of Florida

People needed

79

Starts

2015-06-06

Expected to finish

2021-12-31

Last updated by the study team

2022-10-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• severe, mild-moderate or no pulmonary arterial hypertensive subjects

You may not qualify if…

• Patients with pulmonary hypertension due to left heart disease, lung diseases and / or hypoxia, chronic thromboembolic pulmonary hypertension, and pulmonary hypertension with unclear multifactorial mechanisms.

Where it is running

• Mayo Clinic Jacksonville — Jacksonville, Florida, United States
• Universidade Federal de Ciências da Saúde de Porto Alegre — Porto Alegre, Brazil

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.